RxDoctor Payments Data

Nathan Reed, MD

Clinical Cardiac Electrophysiology · Newburgh, INNPI 1538380993

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,000 of the $12,583 with a category attached, or 87.4%. Abbott accounts for 97.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $8,171 and has fallen 62.8% since, to $3,043 in 2024. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in IN, where the typical reported total is $13,586.

$12,583in general payments, 2019–2025

Across 64 payments — averaging $196.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Amarin Pharma, Inc.$107
  • Medtronic$76
  • Irhythm Technologies, Inc.$38
  • Cardinal Health 200 LLC$24
  • Edwards Lifesciences$20
  • plus $100 from 7 others

What the payments were for

  • Consulting fees$11,00087%
  • Travel & lodging$8607%
  • Food & beverage$7236%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,583 in reported general payments places this provider in the 45th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$33,343
Medicare patients
328
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban360$396,421
XareltoRivaroxaban140$145,070
MultaqDronedarone Hcl19$31,837
Metoprolol Succinate372$5,366
Dofetilide65$3,918
Diltiazem 24hr Er (Cd)Diltiazem Hcl133$3,726
Mexiletine Hcl25$3,427
Amiodarone Hcl175$3,271
Propafenone Hcl ErPropafenone Hcl12$1,671
SotalolSotalol Hcl56$1,413
Warfarin Sodium101$878
Carvedilol91$639
Flecainide Acetate20$393
Propafenone Hcl13$285
Verapamil ErVerapamil Hcl15$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$396,421360 claims
Johnson & JohnsonXarelto$14$145,070140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →